Global

The potential collapse of the CETA agreement jeopardizes EU’s overall trade footing.

The UK's vote to leave the EU was the hot topic - and a source of exasperation - at last week's annual European Health Forum Gastein.

Though comparatively smaller when positioned against some of the country’s neighbors, the pharmaceutical market in the Czech Republic finds itself on a solid growth trajectory, with innovator drug developers grabbing a larger piece of the value pie in the traditionally generics- dominated setting.

The UK is moving closer to aligning its two approaches to regulating drug pricing - the voluntary PPRS and statutory price cuts - but the headaches are likely to continue, writes Leela Barham.

Leela Barham looks at the potential cost to industry of the National Institute for Health and Care Excellence's plans to charge for TAs.

EFPIA's Richard Bergström warns of a return to the "dark ages of medicine" in Europe.

Leela Barham reviews NHS England's proposals for the creation of Regional Medicines Optimisation Committees.

A new campaign in France hopes to build on the nation’s legacy as a life sciences innovator, through championing a fresh pathway to success in areas such as preventative healthcare, advanced diagnostics, medical devices, home care, and big data.

Envigo's new CEO shares with Pharm Exec his vision for the company’s future, the changes he’s seen in the industry, and his thoughts on that thorny subject, Brexit.

Reflector outlines the obstacles ahead for Europe's revamped Innovative Medicines Initiative.

If managed access is to be a widely available option, it makes sense to re-think just how much should be spent on it, writes Leela Barham.

Although Hungary has posted the third-highest economic growth rate in the EU since 2014, its healthcare system is struggling-dictating the need for new efforts if the country is to regain its dominance as a central and eastern European-region trailblazer in the life sciences.

Paul Ranson examines how the UK biopharma must now adapt to a changing landscape.

Leela Barham looks at the EU plans for a European patent, and asks where the UK will fit in after Brexit.

Not yet, says Reflector. But to judge from the European Parliament's latest foray into the subject, there could be plenty of support for such an approach to this complicated subject.

A look at how Europe's new accelerated drug approval scheme can evolve existing review pathways for the better-and take a page from FDA

Dave Handelsman offers a smart approach to dealing with the EMA's new guidelines on the anonymization of clinical trial data.

The UK's Brexit vote has unleashed turbulence in Europe - not least on its pharma sector. Reflector reports.

Only one polling company correctly predicted the UK's Brexit outcome. Graeme Hutton reports.

With one of the oldest populations in the world, Italy faces a daunting question: how can it protect its universal healthcare system while maintaining the country’s high quality standards for public healthcare and ensuring its survival for the next generation? Up to the challenge, Italy must now learn to do more with less.

Companies that want to tap into the full potential of Asia-Pac must boost the role of their regional headquarters.

EU and UK industry groups did their best to display calm and confidence as the world woke up to the reality of Brexit.

A new industry working group explores alternative drug funding options in Europe-and asks key stakeholders in the region to join the discussion.

Do recent trends in the pharma and biotech M&A and equity markets signal a temporary lull - or a permanent drop? Peter Young reports.

Radicals who wield real power at the EMA have gone public with their thinking about the role of regulators in the economic aspects of medicines provision – despite the decades-old EU taboo about linking pricing with authorizations.